Trial Profile
A Phase 2, Open-label Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed Dose Combination in the Treatment of Hepatitis C Virus (HCV) Infection in Pediatric Subjects Undergoing Cancer Chemotherapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Aug 2019
Price :
$35
*
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Acronyms Egypt Peds
- Sponsors Gilead Sciences
- 11 Feb 2019 Status changed from active, no longer recruiting to completed.
- 07 Dec 2018 Planned End Date changed from 1 Apr 2019 to 1 Feb 2019.
- 02 Aug 2018 Status changed from recruiting to active, no longer recruiting.